Predicting the next big trends or business transformations in any industry — much less in biopharmaceuticals — is a crapshoot at best. For instance, at the end of 2016 a lot of experts envisaged at least one CAR-T therapy gaining approval in 2017. Instead, we got two: Gilead’s Yescarta and Kymriah from Novartis. But with Kymriah we also got a new approach to drug pricing — a 30-day money-back guarantee. How many had that approach to drug pricing on their radar?
So how do we best predict who or what might have a big impact on the biopharmaceutical industry in 2018? Although there are no guarantees with this kind of prognostication, we felt seeking the opinions of experienced top biopharma executives would be a good place to start. For answers we reached out to a cross section of biopharmaceutical industry CEOs, from the biggest of Big Pharma, to billionaires, to generic powerhouses, and just about everyone in between.